Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process 
Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
Samsung to Launch First Yongin Chip Plant by 2029 as South Korea Speeds Up Semiconductor Hub 
Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook 
UBS Starts CarTrade Tech With Buy Rating, Sees Strong Earnings Growth and ₹4,000 Target 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand 
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth 
BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report 
Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
DURHAM, N.C., Jan. 07, 2016 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient’s immune system against cancer, announced that Jeff Wolf, Heat’s Chief Executive Officer, will deliver a corporate presentation at the 8th Annual Biotech Showcase™, being held January 11-13, 2016 in San Francisco, CA.
8th Annual Biotech Showcase™
Date: Wednesday, January 13, 2016
Time: 11:30 a.m. Pacific Time
Location: Parc 55 San Francisco Union Square Hotel – Room: Mission II (4th Floor)
Links to a live audio webcast and replay of the presentation may be accessed on Heat Biologics’ website at http://ir.heatbio.com/events-presentations.
About Heat Biologics, Inc.
Heat Biologics, Inc. (Nasdaq:HTBX) is an immuno-oncology company developing novel therapies that activate a patient’s immune system against cancer. Heat’s highly specific T cell-stimulating platform technologies, ImPACT and ComPACT, form the basis of its product candidates. These platforms, in combination with other therapies, such as checkpoint inhibitors, are designed to address three distinct but synergistic mechanisms of action: robust activation of CD8+ “killer” T cells (one of the human immune system’s most potent weapons against cancer); T cell co-stimulation to further enhance patients’ immune response; and reversal of tumor-induced immune suppression. Currently, Heat is conducting a Phase 2 trial with its HS-410 (vesigenurtacel-L) in patients with non-muscle invasive bladder cancer (NMIBC) and a Phase 1b trial with its HS-110 (viagenpumatucel-L) in combination with an anti-PD-1 checkpoint inhibitor to treat patients with non-small cell lung cancer (NSCLC). For more information, please visit www.heatbio.com.
CONTACT: Heat Biologics, Inc. Jennifer Almond Investor and Media Relations 919-240-7133 [email protected]
